da Luca Bonadei | Dic 7, 2019 | Clinical
https://www.adnkronos.com Four initial phase studies were presented at the 61st Congress of the American Society of Hematology (Ash) in Orlando, Florida as the forerunners of a second-generation anti-cancer cellular immunotherapy, which strives to overcome the...
da Luca Bonadei | Dic 7, 2019 | Clinica
https://www.adnkronos.com Quattro studi di fase iniziale presentati al 61esimo Congresso dell’American Society of Hematology (Ash) a Orlando, in Florida sono apripista di un’immunoterapia cellulare anticancro di seconda generazione, che si sforza di superare i...
da Luca Bonadei | Ago 7, 2019 | Business
http://www.globenewswire.com Selecta Biosciences and Asklepios BioPharmaceutical AskBio), announced a strategic partnership to jointly develop, manufacture and commercialize targeted therapeutics for life-changing, next-generation adeno-associated virus (AAV) gene...
da Luca Bonadei | Ago 7, 2019 | Business
http://www.globenewswire.com Selecta Biosciences e Asklepios BioPharmaceutical (AskBio), hanno annunciato l’inizio di una collaborazione strategica per lo sviluppo, la produzione e la commercializzazione congiunta di terapie geniche di nuova generazione con virus...
da Luca Bonadei | Ago 7, 2019 | Clinical
https://www.technologynetworks.com A research team of the Cibio Department of the University of Trento was able to prove the efficacy of CRISPR-Cas, in solving once and for all the problem that causes cystic fibrosis. The disease is caused by a mutation of the...
